Navigation Links
New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Date:6/24/2011

IRVING, Texas and ABBOTT PARK, Ill., June 24, 2011 /PRNewswire/ -- New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate (eGFR). The data were also presented today in a Late-Breaking Clinical Trials session at the 2011 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Prague, Czech Republic.

The Phase 2 dose-finding clinical trial, known as the BEAM study, showed that in patients with moderate to severe chronic kidney disease – defined by an eGFR of 20 to 45 mL/min/1.73m2 – and type 2 diabetes, eGFR at 52 weeks was significantly improved with bardoxolone methyl treatment by up to 10.5 mL/min/1.73m2 in patients receiving 75 mg (p<0.001).

"The published data for bardoxolone methyl suggest that it may have potential to delay kidney disease progression in patients with compromised kidney function," said Dr. David Warnock of the University of Alabama at Birmingham, who presented the findings at the ERA-EDTA session and is the senior author of the article.  "Further study to learn more about the clinical benefits of this drug candidate is warranted."

The multi-center, double-blind, placebo-controlled trial enrolled 227 patients who were randomly assigned to receive placebo, 25, 75 or 150 mg of bardoxolone methyl orally, once daily for 52 weeks.

Specifically, the 52-week data showed:

  • At 52 weeks, patients receiving each of the three tested doses of bardoxolone methyl experienced a statistically significant improvement in eGFR, an important measure of kidney function. Increases were 5.8, 10.5 and 9.3 mL/min/1.73m2 for the 25, 75
    '/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... HAMILTON, Bermuda , April 30 Celtic Pharmaceutical Holdings L.P. ... pharmaceutical industries, announced today the enrolment of the first patient into its ... treatment of onychomycosis (also known as a fungal nail infection).   , ... This Phase III trial is ...
... , April 29 Abraxis BioScience initially ... the former ICN/Valient Pharmaceutical building in Costa Mesa, ... foot building. The "due diligence report" revealed an array ... occupying the building, and once the building purchase was ...
Cached Medicine Technology:Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project 2
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... In her mid-forties and with a lifelong ... Monica K. arrived at JET Uniform & Supply ... and scared. The owners and staff at JET, which had ... to offer jobs to challenged residents like Monica, were patient. ... to begin with the end in mind,” says Stephen Milaney, ...
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable source ... 2015. After a phenomenal and highly successful live tour last ... going out on tour again in 2015 and they will be ... on April 29th in New York City at the cozy Beacon ... Theatre on May 10th. , Fans of the hit show can ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... for the treatment of human viral,and other infectious ... quarter and year ended December 31, 2007. At ... securities totaled,$112.0 million., Significant ...
... March 6, 2008 A study released this ... Healthcare System in California shows that non-polypoid colorectal neoplasms ... than previously thought and may have a greater association ... commonly diagnosed colorectal polyp. The study appears in the ...
... of nursing would,help address the severe nurse faculty ... WASHINGTON, March 6 Today, the American,Association ... Durbin,(D-IL) for introducing the Troops to Nurse Teachers ... when the military and civilian healthcare systems have,been ...
... A study released,this week from researchers at ... shows that non-polypoid colorectal neoplasms or flat,colon lesions, ... and may,have a greater association with cancer compared ... polyp. The study appears in the,March 5 issue ...
... DALLAS, March 6 State Medicaid programs ... innovative,initiative of Affiliated Computer Services, Inc. (NYSE: ... ACS, healthcare clients avoid costly,manual recovery of drug ... enables pharmacies to immediately identify pharmacy,benefit coverage at ...
... offers hope of new diabetes treatments , , THURSDAY, ... levels disable the molecular switch that normally turns off ... insulin levels, a California study finds. , This ... the "sugar-off" switch (CRTC2) may help lower glucose levels ...
Cached Medicine News:Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Colonoscopy used to identify and remove flat colon lesions 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 2Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 4Health News:ACS Launches Medicaid Cost Savings Initiative 2Health News:ACS Launches Medicaid Cost Savings Initiative 3Health News:Constant High Blood Sugar Disables Insulin 'Off' Switch 2
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: